VVM
Versant Venture Management Portfolio holdings
AUM
$82.1M
This Quarter Return
-4.53%
1 Year Return
-26.22%
3 Year Return
+73.87%
5 Year Return
-1.11%
10 Year Return
+1,578.11%
AUM
$513M
AUM Growth
+$513M
(-47%)
Cap. Flow
-$353M
Cap. Flow
% of AUM
-68.73%
Top 10 Holdings %
Top 10 Hldgs %
99.86%
Holding
13
New
1
Increased
1
Reduced
4
Closed
2
Top Buys
| 1 |
Passage Bio
PASG
|
$86.7M |
| 2 |
Adverum Biotechnologies
ADVM
|
$634K |
Top Sells
| 1 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$201M |
| 2 |
CRISPR Therapeutics
CRSP
|
$181M |
| 3 |
Ocular Therapeutix
OCUL
|
$30.3M |
| 4 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$22.7M |
| 5 |
Akero Therapeutics
AKRO
|
$4.64M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CRISPR Therapeutics
CRSP
$4.71B
| $189M | 36.92% | 1,554,960 -1,485,502 | -49% | -$181M |
|
|
2
Passage Bio
PASG
$22.7M
| $86.7M | 16.89% | +4,959,769 | New | +$86.7M |
|
3
Aligos Therapeutics
ALGS
$73.3M
| $74.9M | 14.59% | 3,292,339 | – | – |
|
|
4
Adverum Biotechnologies
ADVM
$64.6M
| $50M | 9.74% | 5,068,233 +64,341 | +1% | +$634K |
|
|
GRTS
5
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $42M | 8.18% | 4,450,638 | – | – |
|
6
Crinetics Pharmaceuticals
CRNX
$2.92B
| $31M | 6.05% | 2,030,616 | – | – |
|
|
7
Akero Therapeutics
AKRO
$3.74B
| $17.9M | 3.49% | 617,727 -160,000 | -21% | -$4.64M |
|
|
FLXN
8
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $11.7M | 2.28% | 1,310,169 -2,532,409 | -66% | -$22.7M |
|
9
Aprea Therapeutics
APRE
$9.09M
| $6.42M | 1.25% | 1,259,662 -166,666 | -12% | -$850K |
|
|
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
| $2.47M | 0.48% | 543,753 | – | – |
|
|
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
| $715K | 0.14% | 101,855 | – | – |
|
|
12
Ocular Therapeutix
OCUL
$2.12B
| – | – | -1,465,384 | Closed | -$30.3M |
|
|
NARI
13
DELISTED
Inari Medical, Inc. Common Stock
NARI
| – | – | -2,298,217 | Closed | -$201M |
|